• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Astellas Venture Management

edit

Astellas Venture Management is a financial organisation which targets its investments in the biotechnologies. They invest in companies that are dedicated to developing new pharmaceutical seeds, or constructing a new drug discovery platform. Their investments are not limited to any geographical location.

Milestones

edit

• 
  Astellas Venture Management invested in Cleave Biosciences. (10/11/11)
  Posted 10/11/11 at 7:32pm via finsmes.com
• 
  Astellas Venture Management invested in Verastem. (7/14/11)
  Posted 7/14/11 at 5:12pm via masshightech.com
• 
  Astellas Venture Management invested in DecImmune Therapeutics. (9/27/10)
  Posted 9/27/10 at 11:08pm via finsmes.com
• 
  Astellas Venture Management invested in Nereus Pharmaceuticals. (6/25/10)
  Posted 6/23/10 at 5:27pm via onbiovc.com
• 
  Astellas Venture Management invested in Lectus Therapeutics. (2/13/06)
  Posted 4/22/10 at 7:04pm via lectustherapeutics.com
• 
  Astellas Venture Management invested in Fate Therapeutics. (11/16/09)
  Posted 11/16/09 at 11:35am via fatetherapeutics.com
• 
  Astellas Venture Management invested in Epizyme. (10/7/09)
  Posted 10/7/09 at 2:46pm via fiercebiotech.com
• 
  Astellas Venture Management invested in Viamet Pharmaceuticals. (7/7/09)
  Posted 9/24/09 at 3:07pm via fiercebiotech.com
• 
  Astellas Venture Management invested in Intradigm Corporation. (1/7/09)
  Posted 6/25/09 at 4:40am via fiercebiotech.com
• 
  Astellas Venture Management invested in F2G. (8/18/08)
  Posted 6/22/09 at 11:37pm via f2g.com
• 
  Astellas Venture Management invested in Inimex Pharmaceuticals. (6/2/08)
  Posted 6/4/09 at 2:03am

Investments

Videos

Sources

1. Cleave Biosciences Raises $42M in Series A Financing (finsmes.com) [edit]
2. Verastem rounds up $32M in second funding (masshightech.com) [edit]
3. DecImmune Therapeutics Receives $1M in Equity Financing; $2.2M Phase II SBIR Funding (finsmes.com) [edit]
4. Nereus Pharmaceuticals, Inc.: Series E $20M (onbiovc.com) [edit]
5. Fate Therapetucis (fatetherapeutics.com) [edit]
6. Epizyme pulls in $32M in VC capital, new investors (fiercebiotech.com) [edit]
7. Viamet gets Big Pharma support in $18M round Read more: http://www.fiercebiotech.com/story/viamet-gets-big-pharma-support-18m-round/2009-07-07#ixzz0S4Hjz62O (fiercebiotech.com) [edit]
8. Intradigm Corporation Closes Final Tranche of $21.4 Million Series B Financing; Philip Haworth, Ph.D. Appointed Chief Executive (fiercebiotech.com) [edit]
9. F2G Ltd completes £6.3million financing round to fund pre-clinical and clinical development (f2g.com) [edit]
10. Capital Funding Report [edit]
11. Lectus Therapeutics closes Series A funding round raising £8.2 million (lectustherapeutics.com) [edit]